184 related articles for article (PubMed ID: 10996844)
1. Expression levels of gp130 in bone marrow stromal cells determine the magnitude of osteoclastogenic signals generated by IL-6-type cytokines.
O'Brien CA; Lin SC; Bellido T; Manolagas SC
J Cell Biochem; 2000 Sep; 79(4):532-41. PubMed ID: 10996844
[TBL] [Abstract][Full Text] [Related]
2. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone.
O'Brien CA; Gubrij I; Lin SC; Saylors RL; Manolagas SC
J Biol Chem; 1999 Jul; 274(27):19301-8. PubMed ID: 10383440
[TBL] [Abstract][Full Text] [Related]
3. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae.
Palmqvist P; Persson E; Conaway HH; Lerner UH
J Immunol; 2002 Sep; 169(6):3353-62. PubMed ID: 12218157
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of gp130 cytokine effects on corticotroph AtT-20 cells--redundancy or specificity of neuroimmunoendocrine modulators?
Auernhammer CJ; Kopp FB; Vlotides G; Dorn F; Isele NB; Spöttl G; Cengic N; Weber MM; Senaldi G; Engelhardt D
Neuroimmunomodulation; 2004; 11(4):224-32. PubMed ID: 15249728
[TBL] [Abstract][Full Text] [Related]
5. Expression of IL-6 receptor and GP130 in mouse bone marrow cells during osteoclast differentiation.
Gao Y; Morita I; Maruo N; Kubota T; Murota S; Aso T
Bone; 1998 May; 22(5):487-93. PubMed ID: 9600782
[TBL] [Abstract][Full Text] [Related]
6. FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins.
Blanchard F; Kinzie E; Wang Y; Duplomb L; Godard A; Held WA; Asch BB; Baumann H
Oncogene; 2002 Sep; 21(41):6264-77. PubMed ID: 12214267
[TBL] [Abstract][Full Text] [Related]
7. Activation of the signal transducer gp130 by interleukin-11 and interleukin-6 is mediated by similar molecular interactions.
Dahmen H; Horsten U; Küster A; Jacques Y; Minvielle S; Kerr IM; Ciliberto G; Paonessa G; Heinrich PC; Müller-Newen G
Biochem J; 1998 May; 331 ( Pt 3)(Pt 3):695-702. PubMed ID: 9560294
[TBL] [Abstract][Full Text] [Related]
8. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.
Jostock T; Müllberg J; Ozbek S; Atreya R; Blinn G; Voltz N; Fischer M; Neurath MF; Rose-John S
Eur J Biochem; 2001 Jan; 268(1):160-7. PubMed ID: 11121117
[TBL] [Abstract][Full Text] [Related]
9. TNF-alpha induces tyrosine phosphorylation and recruitment of the Src homology protein-tyrosine phosphatase 2 to the gp130 signal-transducing subunit of the IL-6 receptor complex.
Bode JG; Schweigart J; Kehrmann J; Ehlting C; Schaper F; Heinrich PC; Häussinger D
J Immunol; 2003 Jul; 171(1):257-66. PubMed ID: 12817006
[TBL] [Abstract][Full Text] [Related]
10. Formation of autocrine loops in human cerebral meningioma tissue by leukemia inhibitor factor, interleukin-6, and oncostatin M: inhibition of meningioma cell growth in vitro by recombinant oncostatin M.
Schrell UM; Koch HU; Marschalek R; Schrauzer T; Anders M; Adams E; Fahlbusch R
J Neurosurg; 1998 Mar; 88(3):541-8. PubMed ID: 9488310
[TBL] [Abstract][Full Text] [Related]
11. Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130.
Hermanns HM; Radtke S; Haan C; Schmitz-Van de Leur H; Tavernier J; Heinrich PC; Behrmann I
J Immunol; 1999 Dec; 163(12):6651-8. PubMed ID: 10586060
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage.
Taguchi Y; Yamamoto M; Yamate T; Lin SC; Mocharla H; DeTogni P; Nakayama N; Boyce BF; Abe E; Manolagas SC
Proc Assoc Am Physicians; 1998; 110(6):559-74. PubMed ID: 9824538
[TBL] [Abstract][Full Text] [Related]
13. Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells.
Bellido T; Stahl N; Farruggella TJ; Borba V; Yancopoulos GD; Manolagas SC
J Clin Invest; 1996 Jan; 97(2):431-7. PubMed ID: 8567964
[TBL] [Abstract][Full Text] [Related]
14. Differential inhibition of IL-6-type cytokine-induced STAT activation by PMA.
Terstegen L; Maassen BG; Radtke S; Behrmann I; Schaper F; Heinrich PC; Graeve L; Gatsios P
FEBS Lett; 2000 Jul; 478(1-2):100-4. PubMed ID: 10922477
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown.
Rowan AD; Koshy PJ; Shingleton WD; Degnan BA; Heath JK; Vernallis AB; Spaull JR; Life PF; Hudson K; Cawston TE
Arthritis Rheum; 2001 Jul; 44(7):1620-32. PubMed ID: 11465713
[TBL] [Abstract][Full Text] [Related]
16. The IL-6 family cytokines, interleukin-6, interleukin-11, oncostatin M, and leukemia inhibitory factor, enhance mast cell growth through fibroblast-dependent pathway in mice.
Gyotoku E; Morita E; Kameyoshi Y; Hiragun T; Yamamoto S; Hide M
Arch Dermatol Res; 2001 Nov; 293(10):508-14. PubMed ID: 11820727
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1.
Kortylewski M; Heinrich PC; Mackiewicz A; Schniertshauer U; Klingmüller U; Nakajima K; Hirano T; Horn F; Behrmann I
Oncogene; 1999 Jun; 18(25):3742-53. PubMed ID: 10391682
[TBL] [Abstract][Full Text] [Related]
18. Imbalanced gp130-dependent signaling in macrophages alters macrophage colony-stimulating factor responsiveness via regulation of c-fms expression.
Jenkins BJ; Grail D; Inglese M; Quilici C; Bozinovski S; Wong P; Ernst M
Mol Cell Biol; 2004 Feb; 24(4):1453-63. PubMed ID: 14749363
[TBL] [Abstract][Full Text] [Related]
19. No inhibition of IL-27 signaling by soluble gp130.
Scheller J; Schuster B; Hölscher C; Yoshimoto T; Rose-John S
Biochem Biophys Res Commun; 2005 Jan; 326(4):724-8. PubMed ID: 15607729
[TBL] [Abstract][Full Text] [Related]
20. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
